Family Tree DNA announces a new SNP product for members of the R1b Y-chromosome haplogroup. The following was posted at the DNA-NEWBIE Yahoogroup by Max Blankfeld, Vice-President of Operations and Marketing at FTDNA:
Many of you have asked about, and have quoted Bennett Greenspanâ€™s comment at the 4th Annual FTDNA Conference on Genetic Genealogy, that in early 2008 weâ€™d be offering the R1b U SNPâ€™s, known as U106 and U152 (also called: S21/S28). We are pleased to announce today that a mini panel containing those SNPâ€™s (as well as U198 and P107) are now available.
Previously, FTDNA could SNP test for R1b1c1 through R1b1c8, but was not testing for R1b1c9, R1b1c10, or R1b1c11. The new SNPs will test for R1b1c9 (U106), R1b1c9b (U198), and R1b1c10 (U152). The P107 SNP is a private SNP within R1b1c9. The R1b tree is available through ISOGG:
With the popular African American Lives series on PBS and numerous news stories and magazine columns, Black History Month often results in increased attention to the genealogy and genetic history of African Americans. I saw a similar increased interest in genetic genealogy last February as well.
The Multiracial Roots of Americans
Diverse has an article entitled “More Americans Are Discovering Their Multiracial Roots.” The article discusses traditional genealogical research, then mentions genetic genealogy – particularly automosal testing:
“One of the more fascinating developments with the new genealogy is the extent to which DNA testing is revealing the multi-racial ancestry of Americans. While thereâ€™s some controversy about the claims of DNA testing firms as to how accurately they can match individuals to ancestors from specific communities and ethnic groups, thereâ€™s a consensus that proper testing can roughly specify a personâ€™s relative mix of his or her ancestorsâ€™ geographic origins.”
Earlier today I posted about the recent updates to the 23andMe service, including an enhanced Gene Journal section and the new Paternal Ancestry.
To get a much more thorough analysis of these new additions, read David P. Hamilton’s “23andMe makes genomics personal â€” and slick” at VentureBeat: lifesciences. Hamilton’s articles are always insightful and well-written, and I would highly recommend this one, especially if you are considering a personal genomics service.
Interestingly, Hamilton gives 23andMe’s website high marks over deCODEme’s similar service. Hsien-Hsien Lei at Eye on DNA recently highlighted (in a post entitled “Ann Turner on Personal Genomics Companies 23andMe vs deCODEme“) an article written by genetic genealogist Ann Turner for the GENEALOGY-DNA mailing list in which she compared the services offered by the two companies. Genetic Future picked up Eye on DNA’s post and wrote “Ann Turner compares 23andMe and deCODEme.”
The Spittoon (23andMe’s blog) announces their new paternal ancestry tool. The information was already obtained from all male participants, so no further sampling is needed. I’m not sure which SNPs they are using to determine haplogroup status, but I’ll look into it.
The Gene Journal (here) adds 30 conditions and traits to bring the total number to almost 60. Interestingly, the conditions and traits are classified as either “Established Research” or “Preliminary Research” based on the studies from which they are derived.
And finally, there is a free demo account that “lets you explore all the features of our service using genetic data from our sample family, the Mendels.” It’s a good way to examine how the genomic data is analyzed and returned to customers using a browser interface.
Bennett Greenspan and Max Blankfeld [I apologize for the previous misspelling of Greenspan's and Blankfeld's names] of the genetic genealogy testing company Family Tree DNA have launched a new service called DNATraits to examine a customer’s DNA for evidence of genetic disease. According to the website, DNATraits:
“provides direct-to-consumer genetic data from tests conducted on individual DNA samples. DNATraits offers tests that are broader in scope and less expensive than any in the world, complete with a free consultation with our genetic counselors before testing (optional) and a free consultation after testing (required) to discuss your results.”
DNATraits claims that their service is different from other DNA testing companies, as explained in their comparison page. Notably, the process of returning the results to the consumer appears to be different from some other companies: the DNA results are returned to the “DNATraits medical doctor for review and confirmation” before being sent to a genetic counselor. The customer is then emailed and directed to set up a telephone appointment with the genetic counselor. After the consultation, the customer is given direct access to all their test results.
GenomeWeb Daily News announced on Friday that DNAPrint Genomics is being purchased by Nanobac Pharmaceuticals (I’ve written about DNAPrint here and here, including about their Doggie DNAPrint product). Here is the press release from Nanobac.
DNAPrint had a big year in 2007 with a number of partnerships and new products, and many people have forgotten or were unaware that the autosomal genetic genealogical tests offered by DNAPrint’s AncestrybyDNA are just a small part of the company’s business. From the Nanobac press release:
“DNAG’s primary objective has been, and Nanobac’s primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG’s flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.”
As I recently mentioned, SeqWright has launched a new Personal Genomics Service. Using a saliva sample, this service will analyze 930,000 SNPs from a customer’s genome using the Affymetrix 6.0 Human SNP Genotyping microarray. SeqWright will then report information back to the customer about “Genetic Health,” “Ancestral Origins,” and “Genealogy.” The cost of the service is $998. According to the website, they “will begin accepting orders for Genetic Profiling Services on Monday January 28 2008.” The official press release is available here.
From the consent form available on the SeqWright website:
“SeqWright will generate its clientâ€™s personal genomic data on the Affymetrix 6.0 Human SNP Genotyping microarray. This Array is capable of recognizing approximately 930,000 unique human SNPâ€™s. However, due to individual sample and test variation the number of SNP genotypes that SeqWright will report for a given individual will be a fraction of those SNPâ€™s.”
Jasia of Creative Gene! Jasia’s winning entry was from a post she wrote about the contest. If Jasia accepts the prize, she will discuss her testing experience or her results either on her blog or here at The Genetic Genealogist, which should be a lot of fun and will help genetic genealogy newbies gain some insight into testing. Congratulations Jasia!
If Jasia doesn’t claim the prize, or decides she doesn’t want it, the runner-up for this contest is Yann of Yann Klimentidis’ Weblog.
Thank you to everyone who wrote about the contest on their blog, subscribed to my feed, subscribed to my mailing list, or left a comment at the original post. Overall, 34 people entered the contest with a total of 117 entries! I met some new readers and read some fantastic posts about the blog. At the end of this post is a list of all the blogs that mentioned the contest.
Remember, you heard it here first! The Houston Chronicle appears to have advance news that two companies, Family Tree DNA and Seqwright, are planning to launch products that will analyze DNA for genes associated with disease, similar to services offered by 23andMe and deCODEme. The news is casually mentioned in a news story published yesterday in that newspaper, and on one of the paper’s blogs.
In the first article, “Public Can Get Genes Tested“, there is a quote from Bennett Greenspan, president and chief executive of Family Tree DNA:
“[FTDNA is] betting that public demand will soar for health testing as well, despite the skepticism of some physicians. Greenspan said Family Tree will begin testing for specific disease genes in a month or two. ‘We’ve been peppered with requests from customers for this kind of service during the last 18 months,’ he said.”
Genizon BioSciences, a private firm in Quebec with about 135 employees, has been awarded $31 million from the Dutch venture capital firm Biotechnology Turnaround Fund to uncover associations between genes and diseases such as obesity, diabetes, and Alzheimer’s.
There are a number of companies concentrating on the correlation between genetics and disease, but the reason that Genizon BioSciences stood out to me is the source of the DNA that the company studies. Genizon uses DNA from descendants of the Quebec Founder Population. This population began with roughly 2,600 individuals who settled Quebec between 1608 and 1760 (although more than 15,000 French had immigrated to Quebec in this period, the vast majority continued to travel westward across Canada) and is estimated to be over 6 million people today. Genizon uses this unique population for a number of beneficial reasons, including: